Wealth Enhancement Advisory Services’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,848
Closed -$246K 3117
2024
Q4
$246K Buy
+2,848
New +$258K ﹤0.01% 2542
2024
Q2
Sell
-3,151
Closed -$286K 2681
2024
Q1
$286K Buy
3,151
+151
+5% +$13.2K ﹤0.01% 1949
2023
Q4
$244K Hold
3,000
﹤0.01% 1971
2023
Q3
$240K Buy
+3,000
New +$242K ﹤0.01% 1880

Other funds holding PPH

Wealth Enhancement Advisory Services's PPH Position: Q1 2025 in Review

Wealth Enhancement Advisory Services sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2025, closing a stake of 2,848 shares — an estimated $246K sold.

Wealth Enhancement Advisory Services first reported a position in PPH in Q3 2023 and held it in 4 quarters. The position peaked at $286K in Q1 2024. 136 funds tracked by Wall St. Rank hold PPH as of Q1 2025.

  • Wealth Enhancement Advisory Services reported no remaining VanEck Pharmaceutical ETF position as of Q1 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 2,848 VanEck Pharmaceutical ETF shares in Q1 2025, an estimated $246K.
  • Wealth Enhancement Advisory Services first reported a position in VanEck Pharmaceutical ETF in Q3 2023 and held it in 4 quarters.
  • Wealth Enhancement Advisory Services's VanEck Pharmaceutical ETF position peaked at $286K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2025, filed 16 Apr 2025.